Novavax, Inc. (NASDAQ:NVAX) Lowered to Sell at BidaskClub

Lloyd Doyle
January 23, 2018

Novavax, Inc. (NVAX) surprised the stock market in its last reported earnings when it earned -$0.15 a piece versus the consensus-estimated -$0.16.

In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. Ladenburg Thalmann Financial Services upped their price target on shares of Novavax to $2.50 and gave the stock a "buy" rating in a report on Thursday, January 11th. Cantor Fitzgerald reiterated a hold rating and issued a $2.00 price objective on shares of Novavax in a research note on Wednesday, November 8th.

Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Finally, Seaport Global Securities restated a "neutral" rating on shares of Novavax in a research note on Friday, October 6th.

Some buy side analysts are also providing their Analysis on Novavax, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 2 said it's a HOLD, and 0 analysts rated the stock as Sell.

Novavax, Inc. (NASDAQ:NVAX) may have great momentum, but how has it been performing relative to the market? The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31. Novavax Inc (NASDAQ:NVAX)'s price to earnings ratio stood at 0. The firm had revenue of $8.35 million during the quarter, compared to the consensus estimate of $6.42 million.

Shares of Novavax Inc (NASDAQ:NVAX) now have an Average Brokerage Recommendation of 2.5, number of Recs in ABR is 8 while industry rank of the company by ABR is 179 out of 265.


In other news, insider Stanley C. Erck bought 100,000 shares of Novavax stock in a transaction that occurred on Thursday, November 9th.

The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 88.04%, and has a solid year to date (YTD) performance of 72.58% which means that the stock is constantly adding to its value from the previous fiscal year end price. 12,477,535 shares of the stock were exchanged. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold".

A number of hedge funds and other institutional investors have recently bought and sold shares of NVAX. KCG Holdings Inc. increased its position in Novavax by 161.0% in the first quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company's stock worth $5,976,000 after buying an additional 1,488,403 shares during the period. Profund Advisors LLC boosted its holdings in Novavax by 0.4% in the second quarter. The shares price has positioned 101.89% over the past quarter while it has directed 44.59% throughout past six months. The Manufacturers Life Insurance Company lifted its position in shares of Novavax by 6.5% during the second quarter. The company reported revenue of $0 in the same period previous year.

Relative strength index (RSI-14) for Novavax, Inc. Voya Investment Management LLC lifted its position in shares of Novavax by 18.6% during the second quarter.

COPYRIGHT VIOLATION NOTICE: "Novavax (NASDAQ:NVAX) Raised to "Buy" at BidaskClub" was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece on another publication, it was illegally copied and reposted in violation of US & worldwide trademark & copyright law.

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER